Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Tricida Inc

Benzinga's Top Ratings Upgrades, Downgrades For October 25, 2022

Upgrades

Benzinga · Oct 25, 2022

Coinbase Global And 3 Other Stocks Insiders Are Buying

Although US stocks closed lower on Thursday, there were a few notable insider trades.

Benzinga · Oct 7, 2022

Insiders Buy More Than $15M Of 3 Stocks

Although the Dow Jones dropped by more than 600 points on Thursday, there were a few notable insider trades.

Benzinga · Jun 10, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Read Why Did Tricida Stop VALOR-CKD Renal Outcomes Trial Early

Tricida Inc (NASDAQ:TCDA) said that, as anticipated, it is stopping its VALOR-CKD renal outcomes trial early for administrative reasons under the existing study protocol to allow for six months of financial runway following topline results, currently anticipated in early Q4 2022. VALOR-CKD trial, initiated in 2018, was designed to evaluate veverimer's ability to…

Benzinga · May 19, 2022

Tricida Flags Delay In Kidney Disease Trial Data Amid Russia-Ukraine Tension

Tricida Inc (NASDAQ: TCDA) updated on the anticipated date for topline data from the VALOR-CKD trial based on the ongoing events in Ukraine.

Benzinga · Mar 3, 2022

Coverage From

Benzinga

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.